BiomX Prepares for Third Quarter 2025 Financial Results
BiomX Inc. (NYSE: PHGE), a leading clinical-stage biotechnology firm, is gearing up to reveal its financial results for the third quarter of 2025. Specializing in pioneering natural and engineered phage therapies to tackle specific pathogenic bacteria, the company aims to provide essential insights into its progress and endeavors.
Scheduled Call for Financial Results
The financial results will be disclosed before the U.S. markets open on a specified date in November 2025. Following this announcement, BiomX will conduct a conference call alongside a live audio webcast at 8:30 a.m. ET. This event is crucial for stakeholders eager to learn about the company's financial standings as well as updates on their ongoing programs.
Joining the Conference Call
To ensure optimal connectivity before the call begins, attendees are encouraged to register at least five minutes prior. For those who prefer not to engage directly with the management team, listening in via the live webcast is recommended.
Key Details of the Call
Conference Call Dial-In & Webcast Information:
Date:
Wednesday, November 12, 2025
Time:
8:30 AM Eastern Time
Conference Call Registration:
Participants can register for the conference call in advance to ensure a smooth experience.
Accessing the Webcast:
The live and archived webcasts will be accessible in the Investors section of BiomX's official website. This allows stakeholders to revisit the discussions and gather insights at their convenience.
About BiomX and Its Innovations
BiomX Inc. is at the forefront of biotechnology, developing innovative phage therapies designed to directly target and eliminate harmful bacteria. Their approach aims to address chronic diseases that have significant unmet medical needs. The company leverages its proprietary BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions tailored to specific bacterial targets.
Future Directions and Commitment
As BiomX continues to evolve, its commitment to pioneering phage therapy remains steadfast. The ongoing research and development initiatives underscore the company's dedication to confronting the pressing challenges of infectious diseases. By targeting bacterial pathogens, BiomX aims not only to improve health outcomes but also to revolutionize treatment paradigms in chronic disease management.
For further inquiries, stakeholders can contact BiomX directly:
BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com
Frequently Asked Questions
What is BiomX's primary focus?
BiomX focuses on developing natural and engineered phage therapies that target specific pathogenic bacteria.
When is BiomX expected to announce its Q3 2025 results?
The results will be announced before the opening of U.S. markets on Wednesday, November 12, 2025.
How can one join the BiomX conference call?
Participants can register for the call, and those who prefer can listen via the live webcast.
What innovations is BiomX pursuing?
BiomX is developing innovative phage cocktail therapies and personalized treatments to address chronic diseases.
Who can be contacted for more information on BiomX?
For information, one can reach out to Ben Cohen, Head of Corporate Communications at BiomX.